Real estate investment trusts are superb vehicles for generating income, but how will they be affected by the Fed's increasing hawkishness? Read More
Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine. He has been a professional investor and independent analyst since 1990. He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.
Analyst Articles
When a company announces earnings, you should dig deeper and scrutinize management's earnings call with analysts and investors. Read More
The housing sector could receive a major tailwind if certain interrelated factors soon unfold. Here's a well-positioned play. Read More
A new name for a famous firm can be the kiss of death, or a prelude to success. Will Ethan Allen's symbol change affect its stock’s price? Read More
Texas Instruments may be a sleeper stock worth watching as its next earnings release approaches. Read More
I am recommending the purchase of United Healthcare June 16, 2017 165 Call (UNH_170616100C16500) up to $5. United is the largest health insurer in the U.S. The stock has fallen in sympathy with Molina Healthcare (NYSE: MOH) as the latter missed its Q$ earnings and announced that it is likely… Read More
Now a value stock, this big pharma is managing its current drugs and its pipeline to perfection. Read More
Sell the Bristol Myers March $50 Call for a 25% three-week profit Read More
I am issuing a buy recommendation for Teradyne (NYSE: TER), a leader in electronic manufacturing equipment testing equipment. Read More
Shares of AMAG Pharmaceuticals (NSDQ: AMAG), a pharmaceutical company focusing on maternal medicine, fell below our Sell Stop of $22 and are now rated SELL. The company’s shares tumbled after it announced positive top line results from its Definitive Pharmacokinetic Study for Makena Subcutaneous Administration and will file a New… Read More